why choose us

First received: February 01, 2023

Clinical Trial: Immunological Tolerance in Patients With Mismatched Kidney Transplants

Study Status: Completed

Recruit Status: RECRUITING

Condition: End Stage Kidney Disease

Study Type: INTERVENTIONAL


Official Title: Use of the Immunomodulating Agent Belumosudil (KD025) After Combined Kidney and Hematopoeitic Stem Cell Transplantation to Induce Transplant Tolerance: A Pilot Study

Brief Summary: This study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3 antigen (at A, B, C, DR) HLA mismatched unrelated living donor kidney and hematopoietic stem cell transplantation.

Read more